Kiniksa Pharmaceuticals Ltd (KNSA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kiniksa Pharmaceuticals Ltd (KNSA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11111
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:バミューダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kiniksa Pharmaceuticals Ltd (Kiniksa Pharmaceuticals) is a clinical-stage biopharmaceutical company focused on discovery, acquisition, development and commercialization of therapeutic medicines for the treatment of auto inflammatory and autoimmune diseases. Its pipeline product portfolio includes Rilonacept used for the treatment of recurrent pericarditis; Mavrilimumab, a monoclonal antibody for treating giant cell arteritis; KPL-716, a monoclonal antibody against prurigo nodularis or atopic dermatitis; KPL-045; and KPL-404. The company has operations with office in the US. Kiniksa Pharmaceuticals is headquartered in Hamilton, Bermuda.

Kiniksa Pharmaceuticals Ltd (KNSA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Kiniksa Pharma Acquires Certain Assets Relating to KPL-716 from Biogen 10
Venture Financing 12
Kiniksa Pharma Raises USD80 Million in Series A Financing 12
Licensing Agreements 13
Kiniksa Pharma Enters into Licensing Agreement with MedImmune 13
Kiniksa Pharma Enters into Option and Licensing Agreement with Primatope Therapeutics 14
Kiniksa Pharma Enters into Licensing Agreement with Regeneron 15
Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 16
Equity Offering 17
Kiniksa Pharma Completes Underwriters Exercise of Over-Allotment Option of IPO of Shares for USD170.1 Million 17
Kiniksa Pharma Raises USD200 Million in Private Placement of Series C Preferred Shares 19
Kiniksa Pharma Raises USD40 Million in Private Placement of Series B Preferred Shares 20
Kiniksa Pharmaceuticals Ltd – Key Competitors 21
Kiniksa Pharmaceuticals Ltd – Key Employees 22
Kiniksa Pharmaceuticals Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Nov 01, 2018: Kiniksa reports third quarter 2018 financial results and pipeline progress 24
Aug 06, 2018: Kiniksa Pharmaceuticals announces second quarter 2018 financial results 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kiniksa Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kiniksa Pharma Acquires Certain Assets Relating to KPL-716 from Biogen 10
Kiniksa Pharma Raises USD80 Million in Series A Financing 12
Kiniksa Pharma Enters into Licensing Agreement with MedImmune 13
Kiniksa Pharma Enters into Option and Licensing Agreement with Primatope Therapeutics 14
Kiniksa Pharma Enters into Licensing Agreement with Regeneron 15
Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 16
Kiniksa Pharma Completes Underwriters Exercise of Over-Allotment Option of IPO of Shares for USD170.1 Million 17
Kiniksa Pharma Raises USD200 Million in Private Placement of Series C Preferred Shares 19
Kiniksa Pharma Raises USD40 Million in Private Placement of Series B Preferred Shares 20
Kiniksa Pharmaceuticals Ltd, Key Competitors 21
Kiniksa Pharmaceuticals Ltd, Key Employees 22
Kiniksa Pharmaceuticals Ltd, Subsidiaries 23

List of Figures
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kiniksa Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kiniksa Pharmaceuticals Ltd (KNSA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Enerjisa Enerji Uretim AS:企業の発電所・SWOT分析2018
    Enerjisa Enerji Uretim AS - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • Nh Foods Ltd:企業の戦略・SWOT・財務分析
    Nh Foods Ltd - Strategy, SWOT and Corporate Finance Report Summary Nh Foods Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Hung Hing Printing Group Limited:企業の戦略・SWOT・財務情報
    Hung Hing Printing Group Limited - Strategy, SWOT and Corporate Finance Report Summary Hung Hing Printing Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • KnowBe4 Inc:企業の戦略的SWOT分析
    KnowBe4 Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • 3M Company:戦略・SWOT・企業財務分析
    3M Company - Strategy, SWOT and Corporate Finance Report Summary 3M Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Aurora Health Care Inc:企業の戦略的SWOT分析
    Aurora Health Care Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Ithaca Energy Inc. (IAE)-石油・ガス分野:企業M&A・提携分析
    Summary Ithaca Energy Inc. (Ithaca) is an oil and gas company, which explores for, develops, and produces oil and gas in the North Sea. It focuses on the appraisal and development of undeveloped discoveries and the exploitation of its existing UK producing asset portfolio. The company has a portfoli …
  • Kleo Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Kleo Pharmaceuticals Inc (Kleo Pharmaceuticals) is a biotechnology company that develops small molecules in the field of immunotherapy to emulate biologics. The company provides adaptable technology platforms such as antibody recruiting molecules (ARMs) and synthetic antibody mimics (SyAMs) …
  • Dongfang Electric Corporation Ltd (1072)-エネルギー分野:企業M&A・提携分析
    Summary Dongfang Electric Corporation Ltd (DEC) a subsidiary of Dongfang Electric Corporation, is a power equipment and services company. It designs, manufactures, and sells power generation equipment, including turbines for hydro, thermal, and nuclear power generation, wind turbine generator sets, …
  • Hybio Pharmaceutical Co Ltd (300199):製薬・医療:M&Aディール及び事業提携情報
    Summary Hybio Pharmaceutical Co Ltd (Hybio) is a peptide pharmaceutical company that develops and manufactures of polypeptide drugs. The company offers peptide finished dosage products and peptide active pharmaceutical ingredients. Its finished dosage products include desmopressin for injection, ter …
  • Total SA (FP):電力:M&Aディール及び事業提携情報
    Summary Total SA (Total) is an integrated global energy company that discovers, produces, refines and markets oil and gas, and also manufactures petrochemicals. It carries out drilling, oil and gas production, processing, transportation, refining and petrochemical production, storage and distributio …
  • Kanika Hotels Public Company Limited:企業の戦略・SWOT・財務分析
    Kanika Hotels Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Kanika Hotels Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Applebee’s Restaurants LLC:戦略・SWOT・企業財務分析
    Applebee's Restaurants LLC - Strategy, SWOT and Corporate Finance Report Summary Applebee's Restaurants LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • The Chugoku Electric Power Co Inc:発電所・企業SWOT分析
    The Chugoku Electric Power Co Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Ziehm Imaging GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Ziehm Imaging GmbH (Ziehm Imaging) is a medical device company that develops, produce and markets mobile X-ray based imaging solutions. The company's products include c-arms with flat panel detectors, c-arms with 3D imaging and c-arms with image intensifier. It offers Ziehm Vision RFD 3D, 3D …
  • Mersana Therapeutics Inc (MRSN):製薬・医療:M&Aディール及び事業提携情報
    Summary Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp is a clinical-stage biopharmaceutical company that offers antibody drug conjugate to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes F …
  • FHI 360:企業の戦略的SWOT分析
    FHI 360 - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Chugai Pharmaceutical Co., Ltd.:企業の戦略・SWOT・財務情報
    Chugai Pharmaceutical Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Chugai Pharmaceutical Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Petroleo Brasileiro SA:企業の戦略・SWOT・財務情報
    Petroleo Brasileiro SA - Strategy, SWOT and Corporate Finance Report Summary Petroleo Brasileiro SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • 3D Systems Corporation:企業の戦略・SWOT・財務情報
    3D Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary 3D Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆